201 related articles for article (PubMed ID: 15110630)
21. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
[TBL] [Abstract][Full Text] [Related]
22. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients?
Marin JG; Levine M; Ensom MH
Ther Drug Monit; 2006 Oct; 28(5):637-42. PubMed ID: 17038878
[TBL] [Abstract][Full Text] [Related]
23. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
24. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
Cole E; Deshpande R
Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
[TBL] [Abstract][Full Text] [Related]
25. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporine therapeutic monitoring with Cmax in kidney transplant recipients: does it fit for all populations?
El-Agroudy AE; Ismail AM; Nassar M; Ghoneim MA
Exp Clin Transplant; 2008 Dec; 6(4):282-6. PubMed ID: 19338490
[TBL] [Abstract][Full Text] [Related]
27. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic drug monitoring of cyclosporine.
Jorga A; Holt DW; Johnston A
Transplant Proc; 2004 Mar; 36(2 Suppl):396S-403S. PubMed ID: 15041374
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B
Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687
[TBL] [Abstract][Full Text] [Related]
30. Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression.
Cardinal H; Barama AA; Fradet V; Lallier M; Lévesque R; St Louis G; Hébert MJ; Girardin C; Pâquet M; Daloze P
Transplant Proc; 2004 Mar; 36(2 Suppl):448S-450S. PubMed ID: 15041384
[TBL] [Abstract][Full Text] [Related]
31. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic monitoring and outcomes of cyclosporine.
Pollard SG
Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
[TBL] [Abstract][Full Text] [Related]
33. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
35. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
Ray JE; Keogh AM; McLachlan AJ
J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporine in pediatric kidney transplantation.
Pape L; Ehrich JH; Offner G
Transplant Proc; 2004 Mar; 36(2 Suppl):203S-207S. PubMed ID: 15041337
[TBL] [Abstract][Full Text] [Related]
37. Abbreviated three-point kinetic profile in the 12-hour area under the curve for pharmacokinetic monitoring of cyclosporine.
Serino F; Citterio F; Pozzetto U; Grevel J; Castagneto M
Transplant Proc; 1994 Oct; 26(5):2807-8. PubMed ID: 7940882
[No Abstract] [Full Text] [Related]
38. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
39. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
[TBL] [Abstract][Full Text] [Related]
40. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
